Clinical and pharmacological implications of time to treatment with interleukin-1 blockade in ST-segment elevation myocardial infarction

MG Del Buono, JI Damonte, F Moroni… - … of Pharmacology and …, 2023 - ASPET
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …

Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot …

A Abbate, MC Kontos, NA Abouzaki… - The American journal of …, 2015 - Elsevier
Two pilot studies of interleukin-1 (IL-1) blockade in ST-segment elevation myocardial
infarction (STEMI) showed blunted acute inflammatory response and overall favorable …

Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction

A Abbate, CR Trankle, LF Buckley… - Journal of the …, 2020 - Am Heart Assoc
Background ST‐segment–elevation myocardial infarction is associated with an intense
acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 …

Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical …

A Abbate, GF Wohlford, MG Del Buono… - European Heart …, 2022 - academic.oup.com
Aims ST-segment elevation myocardial infarction (STEMI) is associated with an intense
acute inflammatory response and an increased risk of death and heart failure (HF). In this …

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction

MG Del Buono, JI Damonte, CR Trankle, D Kadariya… - Scientific Reports, 2022 - nature.com
Leukocytosis is a common finding in patients with ST elevation myocardial infarction
(STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre …

Response to interleukin-1 blockade with anakinra in women and men with ST-segment elevation myocardial infarction

G Corna, M Golino, AH Talasaz… - Minerva cardiology …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Interleukin-1 blockade with anakinra reduces high-sensitivity C-reactive protein
(hsCRP) levels and prevents heart failure (HF) events after ST-segment myocardial …

Impact of C-reactive protein levels and role of anakinra in patients with ST-elevation myocardial infarction

F Moroni, G Corna, MG Del Buono, M Golino… - International journal of …, 2024 - Elsevier
Background Interleukin-1 blockade with anakinra reduces C-reactive protein (CRP) levels
and prevents heart failure (HF) events after ST-segment myocardial infarction (STEMI). The …

Rationale and design of the Virginia Commonwealth University–Anakinra Remodeling Trial‐3 (VCU‐ART3): A randomized, placebo‐controlled, double‐blinded …

BW Van Tassell, MJ Lipinski, D Appleton… - Clinical …, 2018 - Wiley Online Library
There is clear association between the intensity of the acute inflammatory response during
acute myocardial infarction (AMI) and adverse prognosis after AMI. Interleukin‐1 (IL‐1) is a …

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra …

A Abbate, MC Kontos, JD Grizzard… - The American journal of …, 2010 - Elsevier
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which
interleukin-1 (IL-1) plays a central role. The IL-1 receptor antagonist is a naturally occurring …

[HTML][HTML] Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia commonwealth university anakinra …

A Abbate, MC Kontos, JD Grizzard… - The American journal …, 2013 - ncbi.nlm.nih.gov
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which
interleukin-1 (IL-1) plays a central role. The IL-1 receptor antagonist is a naturally occurring …